• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ingef 研究数据库的抽样策略、特征和代表性。

Sampling strategy, characteristics and representativeness of the InGef research database.

机构信息

InGef - Institute for Applied Health Research Berlin GmbH [Institut für angewandte Gesundheitsforschung Berlin GmbH], Germany.

InGef - Institute for Applied Health Research Berlin GmbH [Institut für angewandte Gesundheitsforschung Berlin GmbH], Germany.

出版信息

Public Health. 2022 May;206:57-62. doi: 10.1016/j.puhe.2022.02.013. Epub 2022 Apr 1.

DOI:10.1016/j.puhe.2022.02.013
PMID:35378455
Abstract

OBJECTIVES

The aim of this study was to describe the sampling strategy as well as characteristics and the external validity of a representative sample database drawn from the German InGef research database.

STUDY DESIGN

This is a retrospective cohort study using anonymized claims data for the year 2019.

METHODS

The InGef research database is an anonymized healthcare database with longitudinal claims data from approximately 8.8 Mio insurees. A sample of four million insurees was drawn intended to be representative for the German population with respect to age, sex and region. In addition to demographic information, data on hospitalization rates, mortality rates and drug prescription rates were analysed from the InGef sample database for the year 2019 to demonstrate validity and representativeness. Corresponding national reference data were obtained from official sources.

RESULTS

The distributions of sex and age were similar in the InGef sample database and Germany (proportion of women: 50.8% vs 50.7%; mean age: 44.1 vs 43.9 years). The proportion of insurees living in the eastern part of Germany was lower in the InGef sample database (16.5% vs 19.5%). There was good accordance with German reference data with respect to hospitalization rates and overall mortality rates. Prescription rates for the 20 most often reimbursed drug classes were slightly higher in the InGef sample database.

CONCLUSIONS

The InGef sample database shows good overall agreement with the German population on measures of morbidity, mortality and drug usage.

摘要

目的

本研究旨在描述德国 InGef 研究数据库中代表性样本数据库的抽样策略以及特征和外部有效性。

研究设计

这是一项使用 2019 年匿名索赔数据的回顾性队列研究。

方法

Ingef 研究数据库是一个匿名的医疗保健数据库,包含来自约 880 万被保险人的纵向索赔数据。抽取了四百万名被保险人的样本,旨在在年龄、性别和地区方面代表德国人口。除了人口统计信息外,还从 InGef 样本数据库中分析了 2019 年的住院率、死亡率和药物处方率数据,以证明有效性和代表性。相应的国家参考数据从官方来源获得。

结果

Ingef 样本数据库和德国的性别和年龄分布相似(女性比例:50.8%对 50.7%;平均年龄:44.1 对 43.9 岁)。Ingef 样本数据库中居住在德国东部的被保险人比例较低(16.5%对 19.5%)。在住院率和总体死亡率方面,与德国参考数据有很好的一致性。Ingef 样本数据库中 20 种最常报销药物类别的处方率略高。

结论

在发病率、死亡率和药物使用方面,Ingef 样本数据库与德国人口总体上具有良好的一致性。

相似文献

1
Sampling strategy, characteristics and representativeness of the InGef research database.Ingef 研究数据库的抽样策略、特征和代表性。
Public Health. 2022 May;206:57-62. doi: 10.1016/j.puhe.2022.02.013. Epub 2022 Apr 1.
2
Characteristics and external validity of the German Health Risk Institute (HRI) Database.德国健康风险研究所(HRI)数据库的特征与外部效度。
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9. doi: 10.1002/pds.3895. Epub 2015 Nov 3.
3
Basic characteristics and representativeness of the German Disease Analyzer database
.德国疾病分析器数据库的基本特征及代表性
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466. doi: 10.5414/CP203320.
4
Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies.用于药物流行病学和药物经济学研究的“疾病分析仪”患者数据库的有效性和代表性。
Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26. doi: 10.5414/cpp47617.
5
Mortality in the German Pharmacoepidemiological Research Database (GePaRD) compared to national data in Germany: results from a validation study.德国药物流行病学研究数据库(GePaRD)中的死亡率与德国全国数据的比较:一项验证研究的结果。
BMC Public Health. 2015 Jun 20;15:570. doi: 10.1186/s12889-015-1943-7.
6
Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.复发缓解型多发性硬化症患者的流行病学、特征和治疗以及高疾病活动度的发生率:基于德国索赔数据的真实世界证据。
PLoS One. 2020 May 1;15(5):e0231846. doi: 10.1371/journal.pone.0231846. eCollection 2020.
7
Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data.德国亨廷顿病患者的流行病学和医疗保健利用情况:基于德国索赔数据的真实世界证据。
BMC Neurol. 2019 Dec 10;19(1):318. doi: 10.1186/s12883-019-1556-3.
8
New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study.德国抗中性粒细胞胞浆抗体相关性血管炎的流行病学新见解:一项索赔数据分析研究的结果。
Rheumatology (Oxford). 2021 Oct 2;60(10):4868-4873. doi: 10.1093/rheumatology/keaa924.
9
German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
.德国纵向处方数据库(LRx):特征描述、在药物流行病学研究中的应用及局限性
Int J Clin Pharmacol Ther. 2024 Jan;62(1):20-28. doi: 10.5414/CP204485.
10
Investigation of the representativeness of the German IQVIA Vaccine Analyzer database.德国IQVIA疫苗分析仪数据库代表性调查。
Int J Clin Pharmacol Ther. 2022 Feb;60(2):79-86. doi: 10.5414/CP204098.

引用本文的文献

1
Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany.滤泡性淋巴瘤或弥漫性大B细胞淋巴瘤:德国基于人群的流行病学和健康经济学分析
Ann Hematol. 2025 Sep 2. doi: 10.1007/s00277-025-06592-8.
2
Can pre-existing medical conditions explain occupational differences in COVID-19 disease severity? An analysis of 3.17 million people insured in Germany.既往存在的健康状况能否解释新冠病毒病严重程度的职业差异?对德国317万参保人员的分析。
Scand J Work Environ Health. 2025 Sep 1;51(5):380-393. doi: 10.5271/sjweh.4242. Epub 2025 Aug 9.
3
Speech-language therapy and occupational therapy for patients with mild cognitive impairment and dementia: a retrospective cohort study using German health claims data.
针对轻度认知障碍和痴呆患者的言语语言治疗和职业治疗:一项使用德国健康保险数据的回顾性队列研究。
BMC Health Serv Res. 2025 Aug 5;25(1):1026. doi: 10.1186/s12913-025-13149-y.
4
Impact of Revised Vaccination Recommendations for Mature Infants on Premature Infants' Vaccination Compliance in Germany.德国针对大龄婴儿修订后的疫苗接种建议对早产儿疫苗接种依从性的影响
Infect Dis Ther. 2025 Jul 17. doi: 10.1007/s40121-025-01173-8.
5
Dilemma of missing specific disease codes: an approach to assess the incidence and prevalence of a rare nephrology disease.特定疾病编码缺失的困境:一种评估罕见肾脏病发病率和患病率的方法。
BMC Nephrol. 2025 Jul 3;26(1):346. doi: 10.1186/s12882-025-04271-4.
6
Decreasing prevalence or increase in unregistered cases of bulimia nervosa in children and adolescents in Germany? A comparison using representative claims data pre- vs. intra-COVID-19 pandemic.德国儿童和青少年神经性贪食症的患病率下降还是未登记病例增加?一项使用COVID-19大流行前与流行期间代表性索赔数据的比较。
Eat Weight Disord. 2025 Mar 21;30(1):30. doi: 10.1007/s40519-025-01738-z.
7
Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data.真性红细胞增多症的患病率、发病率及血栓栓塞事件:一项基于德国纵向健康保险数据的研究
Ann Hematol. 2025 Jan;104(1):347-360. doi: 10.1007/s00277-025-06192-6. Epub 2025 Feb 10.
8
Burden of coeliac disease in Germany: real-world insights from a large retrospective health insurance claims database analysis.德国乳糜泻负担:来自大型回顾性健康保险理赔数据库分析的真实世界见解
Therap Adv Gastroenterol. 2025 Feb 4;18:17562848251314803. doi: 10.1177/17562848251314803. eCollection 2025.
9
Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.德国白塞病的流行病学与治疗:一项医保索赔数据库研究
J Eur Acad Dermatol Venereol. 2025 May;39(5):1017-1027. doi: 10.1111/jdv.20489. Epub 2024 Dec 12.
10
A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany.德国重症疾病进展高危成人中与 COVID-19 相关住院负担的回顾性索赔数据分析
Infect Dis Ther. 2025 Jan;14(1):149-165. doi: 10.1007/s40121-024-01088-w. Epub 2024 Dec 8.